BSN HESI 315 Pharmacology Exam V1 Practice Test
Actual 2024/2025 with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (10
Questions)
Q1: A patient with liver cirrhosis is prescribed a drug that undergoes extensive
hepatic metabolism. Which pharmacokinetic parameter is most likely to be altered?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: C
Rationale: Hepatic metabolism (biotransformation) is significantly impaired in liver
disease; drugs metabolized by the liver will have decreased clearance, prolonged
half-life, and increased risk of toxicity.
Q2: The nurse is administering a medication with a narrow therapeutic index. Which
action is most important?
A. Administer the medication with food to enhance absorption
B. Monitor serum drug levels closely to maintain concentrations within the
therapeutic range
,C. Double the dose if the patient reports no effect
D. Discontinue the medication if mild side effects occur
Correct Answer: B
Rationale: Narrow therapeutic index drugs have a small margin between therapeutic
and toxic doses; therapeutic drug monitoring ensures efficacy while preventing
toxicity.
Q3: A drug that binds to a receptor and produces a response is classified as:
A. An antagonist
B. An agonist
C. A partial antagonist
D. An inverse agonist
Correct Answer: B
Rationale: An agonist binds to a receptor and activates it, producing a biological
response; antagonists bind without activating, blocking agonist effects.
Q4: Which factor increases the volume of distribution (Vd) of a lipophilic drug?
A. Decreased body fat
B. Increased plasma protein binding
C. Increased body fat
D. Decreased tissue perfusion
Correct Answer: C
, Rationale: Lipophilic drugs distribute extensively into adipose tissue; increased body
fat expands the apparent volume of distribution, potentially prolonging drug half-life.
Q5: A patient with renal failure is receiving a drug primarily eliminated by the kidneys.
Which adjustment should the nurse anticipate?
A. Increased dosing frequency
B. Decreased dose or increased dosing interval
C. No adjustment needed
D. Switch to the intravenous route only
Correct Answer: B
Rationale: Renal impairment reduces drug elimination, increasing half-life and risk of
accumulation; dose reduction or interval prolongation maintains therapeutic levels
while preventing toxicity.
Q6: The term "first-pass effect" refers to:
A. The initial distribution of a drug into tissues
B. The metabolism of an orally administered drug by the liver before it reaches
systemic circulation
C. The first dose of a medication given to a patient
D. The initial binding of a drug to plasma proteins
Correct Answer: B
Rationale: The first-pass effect is the hepatic metabolism of orally administered
drugs absorbed from the GI tract via the portal circulation before they enter systemic
circulation, reducing bioavailability.
Actual 2024/2025 with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (10
Questions)
Q1: A patient with liver cirrhosis is prescribed a drug that undergoes extensive
hepatic metabolism. Which pharmacokinetic parameter is most likely to be altered?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: C
Rationale: Hepatic metabolism (biotransformation) is significantly impaired in liver
disease; drugs metabolized by the liver will have decreased clearance, prolonged
half-life, and increased risk of toxicity.
Q2: The nurse is administering a medication with a narrow therapeutic index. Which
action is most important?
A. Administer the medication with food to enhance absorption
B. Monitor serum drug levels closely to maintain concentrations within the
therapeutic range
,C. Double the dose if the patient reports no effect
D. Discontinue the medication if mild side effects occur
Correct Answer: B
Rationale: Narrow therapeutic index drugs have a small margin between therapeutic
and toxic doses; therapeutic drug monitoring ensures efficacy while preventing
toxicity.
Q3: A drug that binds to a receptor and produces a response is classified as:
A. An antagonist
B. An agonist
C. A partial antagonist
D. An inverse agonist
Correct Answer: B
Rationale: An agonist binds to a receptor and activates it, producing a biological
response; antagonists bind without activating, blocking agonist effects.
Q4: Which factor increases the volume of distribution (Vd) of a lipophilic drug?
A. Decreased body fat
B. Increased plasma protein binding
C. Increased body fat
D. Decreased tissue perfusion
Correct Answer: C
, Rationale: Lipophilic drugs distribute extensively into adipose tissue; increased body
fat expands the apparent volume of distribution, potentially prolonging drug half-life.
Q5: A patient with renal failure is receiving a drug primarily eliminated by the kidneys.
Which adjustment should the nurse anticipate?
A. Increased dosing frequency
B. Decreased dose or increased dosing interval
C. No adjustment needed
D. Switch to the intravenous route only
Correct Answer: B
Rationale: Renal impairment reduces drug elimination, increasing half-life and risk of
accumulation; dose reduction or interval prolongation maintains therapeutic levels
while preventing toxicity.
Q6: The term "first-pass effect" refers to:
A. The initial distribution of a drug into tissues
B. The metabolism of an orally administered drug by the liver before it reaches
systemic circulation
C. The first dose of a medication given to a patient
D. The initial binding of a drug to plasma proteins
Correct Answer: B
Rationale: The first-pass effect is the hepatic metabolism of orally administered
drugs absorbed from the GI tract via the portal circulation before they enter systemic
circulation, reducing bioavailability.
